References
- Weiner J, Shumacher GE. Psychotropic drug therapy knowledge of health care practitioners. Am J Hosp Pharm 1976; 33: 237–41
- Gottlieb RM, Nappi T, Strain JJ. The physician's knowledge of psychotropic drugs: Preliminary results. Am J Psychiatry 1978; 135: 29–32
- Petersen T, Dording C, Neault NB, Kornbluh R, Alpert JE, Nierenberg AA, et al. A survey of prescribing patterns in the treatment of depression. Prog Neuropsychopharmacol Biol Psychiatry 2002; 26: 177–87
- Hu XH, Bull SA, Hunkeler EM, Ming E, Lee JY, Fireman B, et al. Incidence and duration of side effects and those rated as bothersome with selective serotonin reuptake inhibitor treatment for depression: Patient report versus physician estimate. J Clin Psychiatry 2004; 65: 959–65
- Wiholm B-E, Olsson S, Moore N, Wood S. Spontaneous reporting systems outside the United States. Pharmacoepidemiology2nd edition, BL Strom. John Wiley & Sons, Chichester 1994; 139–55
- Bäckström M, Mjörndal T, Dahlqvist R. Under-reporting of serious drug reactions in Sweden. Pharmacoepidemiol Drug Saf 2004; 3: 483–7
- Eland IA, Belton KJ, van Grootheest AC, Meiners AP, Rawlins MD, Stricker BH. Attitudinal survey of voluntary reporting of adverse drug reactions. Br J Clin Pharmacol 1999; 48: 623–7
- Tisonova J, Szalayova A, Kriska M, Gibala P, Foltan V. Factors influencing the spontaneous reporting of adverse drug reactions – The experience of the Slovak Republic. Pharmacoepidemiol Drug Saf 2004; 13: 333–7
- Tubert-Bitter P, Haramburu F, Begaud B, Chaslerie A, Abraham E, Hagry C. Spontaneous reporting of adverse drug reactions: Who reports and what?. Pharmacoepidemiol Drug Saf 1998; 7: 323–9
- Belton, KJ and The European Pharmacovigilance Research Group. Attitude survey of adverse drug reactions reporting by health care professionals across the European Union. Eur J Clin Pharmacol 1997;52:423–7.
- Hasford J, Goettler M, Munter KH, Müller-Oerlinghausen B. Physicians’ knowledge and attitudes regarding the spontaneous reporting system for adverse drug reactions. J Clin Epidemiol 2002; 55: 945–50
- Drug Consumption in Norway 1998–2002. Nasjonalt folkehelseinstitutt (Norwegian Institute of Public Health), Oslo; 2003.
- Schafer H. Post-approval drug research: Objectives and methods. Pharmacopsychiatry 1997; 30 Suppl. 1: 4–8
- Bull SA, Hunkeler EM, Lee JY, Rowland CR, Williamson TE, Schwab JR, et al. Discontinuing or switching selective serotonin reuptake inhibitors. Ann Pharmacother 2002; 36: 578–84
- Geddes J, Freemantle N, Harrison P, Bebbington P. Atypical antipsychotics in the treatment of schizophrenia: Systematic overview and meta-regression analysis. BMJ 2000; 321: 1371–6
- Bäckström M, Mjörndal T, Dahlqvist R, Nordkvist-Olsson T. Attitudes to reporting adverse drug reactions in Northern Sweden. Eur J Clin Pharmacol 2000; 56: 729–32
- Eldholm RS, Bergheim TS, Slørdal L, Spigset O. Hvilken informasjon gis om bivirkninger av nye legemidler?. Tidsskr Nor Laegeforen 2003; 123: 2414–7
- Song F, Freemantle N, Sheldon TA, House A, Watson P, Long A, et al. Selective serotonin reuptake inhibitors: Meta-analysis of efficacy and tolerability. BMJ 1993; 306: 683–7
- Montgomery SA, Henry J, McDonald G, Dinan T, Lader M, Hindmarch I, et al. Selective serotonin reuptake inhibitors: Meta-analysis of discontinuation rates. Int Clin Psychopharmacol 1994; 9: 47–53
- Chakos M, Lieberman J, Hoffmann E, Bradford D, Sheitman B. Effectiveness of second-generation antipsychotics in patients with treatment-resistant schizophrenia: A review and meta-analysis of randomized trials. Am J Psychiatry 2001; 158: 518–26
- Leucht S, Wahlbeck K, Hamann J, Kissling W. New generation antipsychotics versus low-potency conventional antipsychotics: A systematic review and meta-analysis. Lancet 2003; 361: 1581–9
- http://www.lovdata.no/for/sf/hd/td-19991222-1559-035.html#11-7.
- Belton KJ, Lewis SC, Payne S, Rawlins MD, Wood SM. Attitudinal survey of adverse drug reactions reporting by medical practitioners in the United Kingdom. Br J Clin Pharmacol 1995; 39: 223–6
- Stahl SM. Antipsychotic agents. Stahl SM. Essential psychopharmacology2nd edition. Cambridge University Press, Cambridge 2000; 401–58